Risk Assessment and Meningococcal A Conjugate Vaccine Introduction in Africa: The District Prioritization Tool
نویسندگان
چکیده
BACKGROUND A group A meningococcal (MenA) conjugate vaccine has progressively been introduced in the African meningitis belt since 2010. A country-wide risk assessment tool, the District Prioritization Tool (DPT), was developed to help national stakeholders combine existing data and local expertise to define priority geographical areas where mass vaccination campaigns should be conducted. METHODS DPT uses an Excel-supported offline tool that was made available to the countries proposed for immunization campaigns. It used quantitative-qualitative methods, relying predominantly on evidence-based risk scores complemented by expert opinion. RESULTS DPT was used by most of the countries that introduced the group A conjugate vaccine. Surveillance data enabled the computation of severity scores for meningitis at the district level (magnitude, intensity, and frequency). District data were scaled regionally to facilitate phasing decisions. DPT also assessed the country's potential to conduct efficient preventive immunization campaigns while paying close attention to the scope of the geographic extension of the campaigns. The tool generated meningitis district profiles that estimated the number of vaccine doses needed. In each assessment, local meningitis experts contributed their knowledge of local risk factors for meningitis epidemics to refine the final prioritization decisions. CONCLUSIONS DPT proved to be a useful and flexible tool that codified information and streamlined discussion among stakeholders while facilitating vaccine distribution decisions after 2011. DPT methodology may be tailored to prioritize vaccine interventions for other diseases.
منابع مشابه
Meningococcal disease before and after the introduction of meningococcal serogroup C conjugate vaccine. Federal District, Brazil.
OBJECTIVES To analyze the behavior of meningococcal disease in the Federal District, Brazil, from 2005 to 2011, and to assess the direct impact of the meningococcal serogroup C conjugate vaccine. METHODS A descriptive study of cases of meningococcal disease among residents of the Federal District. We included in the study confirmed cases of meningococcal disease reported to the local surveill...
متن کاملEvaluating Cost and Performance for Improved Meningitis Disease Surveillance in Chad
Introduction The costs of addressing specific needs to improve surveillance systems in sub-Saharan Africa are often unknown. For centuries meningococcal meningitis epidemics have occurred every few years in the Sahelian and sub-sahel regions of Africa also referred to as the “African meningitis belt”. A serogroup A meningococcal conjugate vaccine, MenAfriVac®, was licensed in 2009 and introduce...
متن کاملEvolution of meningococcal carriage in serogroups X and Y before introduction of MenAfriVac in the health district of Kaya, Burkina Faso
BACKGROUND The objective of this study was to evaluate the carriage of Neisseria meningitidis (Nm) serogroups X and Y in the health district of Kaya before the introduction of a serogroup A meningococcal conjugate vaccine in Burkina Faso. METHODS A repeated cross-sectional meningococcal carriage study was conducted in 2009 in eight randomly selected villages in the health district of Kaya, Bu...
متن کاملIntroduction of a group A meningococcal conjugate vaccine in sub-Saharan Africa: Cost/savings analysis
متن کامل
The Meningitis Vaccine Project.
Epidemic meningococcal meningitis is an important public health problem in sub-Saharan Africa. Current control measures rely on reactive immunizations with polysaccharide (PS) vaccines that do not induce herd immunity and are of limited effectiveness in those under 2 years of age. Conversely, polysaccharide conjugate vaccines are effective in infants and have consistently shown an important eff...
متن کامل